Management of adjuvant mitotane therapy following resection of adrenal cancer
- 17 June 2012
- journal article
- review article
- Published by Springer Nature in Endocrine
- Vol. 42 (3) , 521-525
Abstract
Whenever adrenal cancer (ACC) is completely removed we should face the dilemma to treat by means of adjuvant therapy or not. In our opinion, adjuvant mitotane is the preferable approach in most cases because the majority of patients following radical removal of an ACC have an elevated risk of recurrence. A better understanding of factors that influence prognosis and response to treatment will help in stratifying patients according to their probability of benefiting from adjuvant mitotane, with the aim of sparing unnecessary toxicity to patients who are likely unresponsive. However, until significant advancements take place, we have to deal with uncertainty using our best clinical judgement and personal experience in the clinical decision process. In the present paper, we present the current evidence on adjuvant mitotane treatment and describe the management strategies of patients with ACC after complete surgical resection. We acknowledge the limit that most recommendations are based on personal experience rather than solid evidence.Keywords
This publication has 38 references indexed in Scilit:
- High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-upEuropean Journal of Endocrinology, 2012
- The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotaneEndocrine-Related Cancer, 2010
- Recurrence of Adrenal Cortical Carcinoma Following Resection: Surgery Alone Can Achieve Results Equal to Surgery Plus MitotaneAnnals of Surgical Oncology, 2009
- Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical CarcinomaJournal of Clinical Oncology, 2009
- Adjuvant Mitotane for Adrenocortical Cancer—A Recurring ControversyThe Journal of Clinical Endocrinology & Metabolism, 2008
- Adjuvant Mitotane in Adrenocortical CarcinomaNew England Journal of Medicine, 2007
- Adjuvant Mitotane Treatment for Adrenocortical CarcinomaNew England Journal of Medicine, 2007
- Adjuvant Mitotane Therapy of Adrenal Cancer — Use and ControversyNew England Journal of Medicine, 2007
- Adrenocortical Carcinoma: Experience in 45 PatientsOncology, 1997
- Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancerCancer, 1993